Home › Compare › APTX vs XYLD

APTX vs XYLD: Dividend Comparison 2026

APTX yields 2083.33% · XYLD yields 11.20%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 APTX wins by $14544499705.96M in total portfolio value
10 years
APTX
APTX
● Live price
2083.33%
Share price
$0.10
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$14544499705.99M
Annual income
$13,289,647,770,778,488.00
Full APTX calculator →
XYLD
Global X S&P 500 Covered Call ETF
● Live price
11.20%
Share price
$38.36
Annual div
$4.30
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.9K
Annual income
$3,351.03
Full XYLD calculator →

Portfolio growth — APTX vs XYLD

📍 APTX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAPTXXYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, APTX + XYLD cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
APTX pays
XYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

APTX
Annual income on $10K today (after 15% tax)
$177,083.33/yr
After 10yr DRIP, annual income (after tax)
$11,296,200,605,161,714.00/yr
XYLD
Annual income on $10K today (after 15% tax)
$952.37/yr
After 10yr DRIP, annual income (after tax)
$2,848.38/yr
At 15% tax rate, APTX beats the other by $11,296,200,605,158,866.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of APTX + XYLD for your $10,000?

APTX: 50%XYLD: 50%
100% XYLD50/50100% APTX
Portfolio after 10yr
$7272249853.01M
Annual income
$6,644,823,885,390,920.00/yr
Blended yield
91.37%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on APTX right now

APTX
Analyst Ratings
2
Buy
5
Hold
1
Sell
Consensus: Hold
Price Target
$1.00
+941.7% upside vs current
Range: $1.00 — $1.00
Altman Z
-14.5
Piotroski
1/9
XYLD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

APTX buys
0
XYLD buys
0
No recent congressional trades found for APTX or XYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAPTXXYLD
Forward yield2083.33% ✓11.20%
Annual dividend / share$2.00$4.30 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$14544499705.99M ✓$25.9K
Annual income after 10y$13,289,647,770,778,488.00 ✓$3,351.03
Total dividends collected$14455710543.57M ✓$20.2K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: APTX vs XYLD ($10,000, DRIP)

YearAPTX PortfolioAPTX Income/yrXYLD PortfolioXYLD Income/yrGap
1← crossover$219,033$208,333.33$10,840$1,120.44+$208.2K → APTX
2$4,499,033$4,264,667.71$11,786$1,249.59+$4.49M → APTX
3$86,681,257$81,867,291.39$12,854$1,397.78+$86.67M → APTX
4$1,566,868,240$1,474,119,294.47$14,063$1,568.33+$1566.85M → APTX
5$26,579,804,805$24,903,255,789.01$15,434$1,765.19+$26579.79M → APTX
6$423,253,588,633$394,813,197,491.25$16,995$1,993.14+$423253.57M → APTX
7$6,328,542,537,504$5,875,661,197,666.76$18,777$2,257.95+$6328542.52M → APTX
8$88,877,753,676,302$82,106,213,161,172.67$20,818$2,566.58+$88877753.66M → APTX
9$1,172,758,817,952,321$1,077,659,621,518,678.10$23,163$2,927.50+$1172758817.93M → APTX
10$14,544,499,705,987,470$13,289,647,770,778,488.00$25,865$3,351.03+$14544499705.96M → APTX

APTX vs XYLD: Complete Analysis 2026

APTX — Stock

Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II/b clinical trial for treating fibromyalgia. It is also developing NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase II/b clinical trial to treat post-traumatic stress disorder; and NYX-458, an NMDAr modulator, which is in Phase II clinical study for the treatment of Parkinson's disease cognitive impairment. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.

Full APTX Calculator →

XYLD — ETF

The Global X S&P 500 Covered Call ETF (XYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe S&P 500 BuyWrite Index.

Full XYLD Calculator →
📬

Get this APTX vs XYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

APTX vs SCHDAPTX vs JEPIAPTX vs OAPTX vs KOAPTX vs MAINAPTX vs QYLDAPTX vs JEPQAPTX vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.